The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | MRD as a marker in follicular lymphoma: importance and limitations
Alessandro Pulsoni, MD, Sapienza University of Rome, Rome, Italy, discusses the importance of measurable residual disease (MRD) as a marker, its limitations and MRD evaluation methods. Prof. Pulsoni thinks MRD can be considered a reliable marker for treatment response in patients with follicular lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
